Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadodiamide
Drug ID BADD_D00985
Description Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
Indications and Usage For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Marketing Status approved; investigational
ATC Code V08CA03
DrugBank ID DB00225
KEGG ID D04284
MeSH ID C064925
PubChem ID 60754
TTD Drug ID D03EEH
NDC Product Code 0407-0691; 0407-0690; 71806-069
UNII 84F6U3J2R6
Synonyms gadodiamide | Gd-DTPA bis-(methylamide) | Gd-DTPA-BMA | Omniscan | Omniscan Unique Softpack
Chemical Information
Molecular Formula C16H28GdN5O9
CAS Registry Number 122795-43-1
SMILES CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.042680%
Injection site pain08.02.03.010; 12.07.03.0110.007113%-
Injection site reaction08.02.03.014; 12.07.03.015--
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.0050.035567%
Loss of consciousness17.02.04.0040.054773%-
Malaise08.01.01.003--
Melaena07.12.02.004; 24.07.02.013---
Mental impairment17.03.03.002; 19.21.02.0030.010670%-
Migraine17.14.02.001; 24.03.05.003---
Movement disorder17.01.02.0100.010670%-
Multiple sclerosis10.04.10.008; 17.16.01.001---
Muscle contractions involuntary15.05.03.008; 17.05.03.0010.007113%-
Muscular weakness15.05.06.001; 17.05.03.0050.035567%
Musculoskeletal pain15.03.04.0070.007113%
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasal congestion22.04.04.0010.015649%
Nausea07.01.07.001--
Nephropathy toxic12.03.01.010; 20.05.03.0020.007113%-
Ocular hyperaemia06.04.05.0040.010670%-
Oedema08.01.07.006; 14.05.06.0100.028454%-
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.0110.014227%
Oral discomfort07.05.05.0010.007113%-
Pain08.01.08.004--
Pain in extremity15.03.04.0100.024897%
Pain of skin23.03.03.0030.017783%
Pallor08.01.03.032; 23.03.03.031; 24.03.04.0010.015649%-
Palpitations02.11.04.0120.029876%
Papule23.03.03.0380.017783%-
Paraesthesia17.02.06.005; 23.03.03.0940.032010%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages